Review



anti gdf11 primary antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems anti gdf11 primary antibody
    Anti Gdf11 Primary Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 28 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/Recombinant+Human%2FMouse%2FRat+GDF-11%2FBMP-11+Protein/pm41637825-94-14-19
    Average 93 stars, based on 28 article reviews
    anti gdf11 primary antibody - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Topical GDF11 accelerates skin wound healing in both type 1 and 2 diabetic mouse models.
    Article Snippet: This study aimed to investigate the role of truncated growth differentiation factor 11 (GDF11), in which the recognition site of Furin from wild-type GDF11 was deleted to enhance the cellular stability, in skin wound healing in the setting of diabetes mellitus (DM) and the underlying mechanisms.. Our study found that both truncated and natural GDF11s effectively accelerated wound healing processes in both T1DM and T2DM mice with a potency compatible to PDGF, bFGF, and EGF, but being much higher than GDF8.. At the cellular level, GDF11 stimulated the proliferation and suppressed HG-induced apoptosis of HSFs.

    Incubation:

    Article Title: Topical GDF11 accelerates skin wound healing in both type 1 and 2 diabetic mouse models.
    Article Snippet: This study aimed to investigate the role of truncated growth differentiation factor 11 (GDF11), in which the recognition site of Furin from wild-type GDF11 was deleted to enhance the cellular stability, in skin wound healing in the setting of diabetes mellitus (DM) and the underlying mechanisms.. Our study found that both truncated and natural GDF11s effectively accelerated wound healing processes in both T1DM and T2DM mice with a potency compatible to PDGF, bFGF, and EGF, but being much higher than GDF8.. At the cellular level, GDF11 stimulated the proliferation and suppressed HG-induced apoptosis of HSFs.

    Article Title: GDF11 inhibits cardiomyocyte pyroptosis and exerts cardioprotection in acute myocardial infarction mice by upregulation of transcription factor HOXA3.
    Article Snippet: .. The protein was transferred to nitrocellulose membranes and blocked with 5% BSA at room temperature for 2 h. Following incubation used the primary antibodies of GDF11 (1:500, cat. no. MAB19581; R&D Systems, MAB19581, Minneapolis, MN, USA), HOXA3 (1:500, cat. no. ab230879; Abcam, Inc., Cambridge, MA, USA), NLRP3 (1:1000, cat. no. 15101; Cell Signaling Technology, Danvers, MA, USA), ASC (1:1000, cat. no. 67824; Cell Signaling Technology, Danvers, MA, USA), cleaved-caspase-1 (1:500, cat. no. 67314; Cell Signaling Technology, Danvers, MA, USA), GSDMD-N (1:500, cat. no. 93709; Cell Signaling Technology, Danvers, MA, USA), and GAPDH (1:1000, cat. no. TA-08; Zhongshanjinqiao, Inc., Beijing, China) in PBS at 4 °C overnight. .. Membranes were incubated with the fluorescence-labeled secondary antibody at room temperature for 1 h (1:10,000; LI-COR, Lincoln, NE, USA).

    Article Title: GDF11 inhibits cardiomyocyte pyroptosis and exerts cardioprotection in acute myocardial infarction mice by upregulation of transcription factor HOXA3
    Article Snippet: .. The protein was transferred to nitrocellulose membranes and blocked with 5% BSA at room temperature for 2 h. Following incubation used the primary antibodies of GDF11 (1:500, cat. no. MAB19581; R&D Systems, MAB19581, Minneapolis, MN, USA), HOXA3 (1:500, cat. no. ab230879; Abcam, Inc., Cambridge, MA, USA), NLRP3 (1:1000, cat. no. 15101; Cell Signaling Technology, Danvers, MA, USA), ASC (1:1000, cat. no. 67824; Cell Signaling Technology, Danvers, MA, USA), cleaved-caspase-1 (1:500, cat. no. 67314; Cell Signaling Technology, Danvers, MA, USA), GSDMD-N (1:500, cat. no. 93709; Cell Signaling Technology, Danvers, MA, USA), and GAPDH (1:1000, cat. no. TA-08; Zhongshanjinqiao, Inc., Beijing, China) in PBS at 4 °C overnight. .. Membranes were incubated with the fluorescence-labeled secondary antibody at room temperature for 1 h (1:10,000; LI-COR, Lincoln, NE, USA).

    Membrane:

    Article Title: Growth Differentiation Factor 11 Promotes Differentiation of MSCs into Endothelial-Like Cells for Angiogenesis
    Article Snippet: Abstract: Background : Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor-β (TGF-β) super family.. It has multiple effects on development, physiology and diseases.. However, the role of GDF11 in the development of mesenchymal stem cells (MSCs) is not clear.

    Article Title: Growth differentiation factor 11 promotes differentiation of MSCs into endothelial‐like cells for angiogenesis
    Article Snippet: .. The samples were separated by SDS‐PAGE, transferred to a polyvinylidene fluoride membrane, and immunoblotted with the following antibodies: GDF11 (DGDF80, R&D Systems,Emeryville, CA,USA), HGF (ab83760, Abcam, USA), VEGFR1 (ET1605‐11,Huabio,China), CD31 (#77699, Cell Signalling TechnologyBoston,MA, USA), VEGFR2 (#9698, following Abs are all from Cell Signalling Technology,USA), phospho‐p44/42 (Thr202/Try204 phospho‐ERK1/2,#4370), p44/42 MAPK (Erk1/2,#4696), BCL2 (#2827), BAX (#14796), Cleaved Caspase3 (#9661), phospho‐Smad2 (Ser465/Ser467,#18338), phospho‐Smad3 (Ser423/425, # 9520), Smad2(#5339), Smad3(#9523), anti‐β‐actin (#3700), EIF4E (R1512‐8,Huabio, China), Phospho‐eIF4E (S209) (ET1608‐66,Huabio, China) and VEGF ( ER30607,Huabio, China),at 4°C overnight. .. After incubation of the membranes with peroxidase‐conjugated secondary antibodies (Cell Signalling Technology,USA), bands were visualized using enhanced chemiluminescence reagents (Bio‐Rad,Los Angeles, CA,USA).

    Control:

    Article Title: Anti-activin A antibodies and uses thereof
    Article Snippet: .. 2.3E−09 3.4E−09 H2aM10965N 3.5E−09 mIgG isotype Non-Blocker control hIgG isotype Non-Blocker Non-Blocker Non-Blocker Non-Blocker control Control 1 8.3E−11 Non-Blocker 5.4E−10 1.1E−09 The bioassay using A204/CAGAx12-Luc cells could also be stimulated by GDF8 (R&D Systems, Cat #788-G8/CF) and GDF11 (R&D Systems, Cat #1958-GD-010/CF). ..

    Bioassay:

    Article Title: Anti-activin A antibodies and uses thereof
    Article Snippet: .. 2.3E−09 3.4E−09 H2aM10965N 3.5E−09 mIgG isotype Non-Blocker control hIgG isotype Non-Blocker Non-Blocker Non-Blocker Non-Blocker control Control 1 8.3E−11 Non-Blocker 5.4E−10 1.1E−09 The bioassay using A204/CAGAx12-Luc cells could also be stimulated by GDF8 (R&D Systems, Cat #788-G8/CF) and GDF11 (R&D Systems, Cat #1958-GD-010/CF). ..

    Isolation:

    Article Title: Growth differentiation factor 11 accelerates liver senescence through the inhibition of autophagy
    Article Snippet: The differentiated non‐transformed mouse hepatocyte cell line alpha mouse liver 12 (AML‐12) (American Type Culture Collection) were cultured in DMEM/F12 medium (11320082; Gibco) supplemented with 10% FBS (Gibco), 1× insulin‐transferrin‐selenium‐G supplement (41400045; Gibco), 40 ng/ml dexamethasone (D4902; Sigma‐Aldrich), 100 IU/ml penicillin, and 100 μg/ml streptomycin (Gibco), and maintained at 37oC in a humidified incubator containing 5% CO 2 gas. .. To determine whether GDF11 could affect hepatocyte senescence, primary hepatocyte isolated from old mice treated with GDF11 (100 ng/ml, 1958‐GD/CF; R&D Systems) for 48 h. To investigate whether the senescence effect of GDF11 was autophagy dependent, rapamycin (0.1 μM) was used to rescue the GDF11‐induced impairment of autophagic activity. .. In some experiments, mTORC1 activity was inhibited by depleting Raptor with specific small interfering RNA (siRNA) (Invitrogen), and TFEB activity was increased by overexpressing TFEB with Ad‐TFEB.

    Activity Assay:

    Article Title: Growth differentiation factor 11 accelerates liver senescence through the inhibition of autophagy
    Article Snippet: The differentiated non‐transformed mouse hepatocyte cell line alpha mouse liver 12 (AML‐12) (American Type Culture Collection) were cultured in DMEM/F12 medium (11320082; Gibco) supplemented with 10% FBS (Gibco), 1× insulin‐transferrin‐selenium‐G supplement (41400045; Gibco), 40 ng/ml dexamethasone (D4902; Sigma‐Aldrich), 100 IU/ml penicillin, and 100 μg/ml streptomycin (Gibco), and maintained at 37oC in a humidified incubator containing 5% CO 2 gas. .. To determine whether GDF11 could affect hepatocyte senescence, primary hepatocyte isolated from old mice treated with GDF11 (100 ng/ml, 1958‐GD/CF; R&D Systems) for 48 h. To investigate whether the senescence effect of GDF11 was autophagy dependent, rapamycin (0.1 μM) was used to rescue the GDF11‐induced impairment of autophagic activity. .. In some experiments, mTORC1 activity was inhibited by depleting Raptor with specific small interfering RNA (siRNA) (Invitrogen), and TFEB activity was increased by overexpressing TFEB with Ad‐TFEB.

    Blocking Assay:

    Article Title: GDF11 replenishment protects against hypoxia-mediated apoptosis in cardiomyocytes by regulating autophagy.
    Article Snippet: GDF11 has been reported to play a critical role in rejuvenating hypertrophy heart, skeletal muscle, and blood vessel regeneration in aged mice.. Whether GDF11 can regulate autophagy in cardiomyocytes remains largely unknown.. Thus, the purpose of the present study was to investigate the effects of GDF11 on cardiomyocyte autophagy induced by hypoxia, in addition to the underlying mechanisms.



    Similar Products

    93
    R&D Systems anti gdf11 primary antibody
    Anti Gdf11 Primary Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/Recombinant+Human%2FMouse%2FRat+GDF-11%2FBMP-11+Protein/pm41637825-94-14-19
    Average 93 stars, based on 1 article reviews
    anti gdf11 primary antibody - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    Eagle Biosciences gdf11 k01 mouse myostatin gdf8 elisa kit
    Gdf11 K01 Mouse Myostatin Gdf8 Elisa Kit, supplied by Eagle Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/Mouse+Myostatin%2FGDF8+ELISA+Kit/bio_rxiv__64898__2026__01__02__697406-102-8-13
    Average 94 stars, based on 1 article reviews
    gdf11 k01 mouse myostatin gdf8 elisa kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    86
    Genechem aav9 cmv gdf11 1 0 1012 vg day
    Aav9 Cmv Gdf11 1 0 1012 Vg Day, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/0+1+1012+aav9+cmv+day+gdf11+vg+%C3%97/pmc12647682-289-21-26
    Average 86 stars, based on 1 article reviews
    aav9 cmv gdf11 1 0 1012 vg day - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Vigene Biosciences aav9 carrying gdf11
    Aav9 Carrying Gdf11, supplied by Vigene Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/aav8/pm41240221-35-1-9
    Average 86 stars, based on 1 article reviews
    aav9 carrying gdf11 - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    93
    R&D Systems gdf11 elisa
    293T cells co-expressing PCSK5 M452I secrete mature ectopic <t>GDF11</t> with intermediate efficiency. A, Catalytically active PCSK5 promotes ectopic GDF11 secretion. Cells were lipofected with 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) plus 100 ng of GDF11, and conditioned medium was collected after 24 hours to measure GDF11 release by ELISA. PCSK5 T288P was included as a catalytically dead control ( 28 ). B, GDF11 release by PCSK5 M452I plus wildtype PCSK5 (PCSK5 WT ) is additive. Cells were treated as in ( A ) and compared with 1.5 ng PCSK5 WT plus 1.5 ng PCSK5 M452I . C, Cotransfection with oncogenic HRAS G12V approximates the level of prenylated HRAS (HRAS prenyl ) in MCF10DCIS.com. 293T cells were lipofected with 2 ng of HRAS G12V and 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) and immunoblotted for HRAS with vinculin and p38 used as loading controls. MCF10A-5E cells are a negative control for HRAS overexpression. D, HRAS G12V cotransfection does not alter the relative GDF11 secretion efficiencies of wildtype PCSK5, PCSK5 M452I , and PCSK5 T288P . Cells were treated as in ( C ) and measured for GDF11 release by ELISA. For ( A ), ( B ), and ( D ), GDF11 ELISA results are normalized to the GDF11-only condition [gray dashed in ( A )] and shown as the mean ± SEM of N = 4 biological replicates. Differences among +GDF11 groups were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis.
    Gdf11 Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/Human+GDF-11%2FBMP-11+DuoSet+ELISA/pmc12671455-75-23-25
    Average 93 stars, based on 1 article reviews
    gdf11 elisa - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    88
    Addgene inc gdf11 secretion assay plx302 gdf11 v5 puro
    293T cells co-expressing PCSK5 M452I secrete mature ectopic <t>GDF11</t> with intermediate efficiency. A, Catalytically active PCSK5 promotes ectopic GDF11 secretion. Cells were lipofected with 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) plus 100 ng of GDF11, and conditioned medium was collected after 24 hours to measure GDF11 release by ELISA. PCSK5 T288P was included as a catalytically dead control ( 28 ). B, GDF11 release by PCSK5 M452I plus wildtype PCSK5 (PCSK5 WT ) is additive. Cells were treated as in ( A ) and compared with 1.5 ng PCSK5 WT plus 1.5 ng PCSK5 M452I . C, Cotransfection with oncogenic HRAS G12V approximates the level of prenylated HRAS (HRAS prenyl ) in MCF10DCIS.com. 293T cells were lipofected with 2 ng of HRAS G12V and 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) and immunoblotted for HRAS with vinculin and p38 used as loading controls. MCF10A-5E cells are a negative control for HRAS overexpression. D, HRAS G12V cotransfection does not alter the relative GDF11 secretion efficiencies of wildtype PCSK5, PCSK5 M452I , and PCSK5 T288P . Cells were treated as in ( C ) and measured for GDF11 release by ELISA. For ( A ), ( B ), and ( D ), GDF11 ELISA results are normalized to the GDF11-only condition [gray dashed in ( A )] and shown as the mean ± SEM of N = 4 biological replicates. Differences among +GDF11 groups were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis.
    Gdf11 Secretion Assay Plx302 Gdf11 V5 Puro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/pLX302+GDF11-V5+puro+(Plasmid+%2383097)/pmc12671455-42-0-5
    Average 88 stars, based on 1 article reviews
    gdf11 secretion assay plx302 gdf11 v5 puro - by Bioz Stars, 2026-10
    88/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology anti gdf11
    293T cells co-expressing PCSK5 M452I secrete mature ectopic <t>GDF11</t> with intermediate efficiency. A, Catalytically active PCSK5 promotes ectopic GDF11 secretion. Cells were lipofected with 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) plus 100 ng of GDF11, and conditioned medium was collected after 24 hours to measure GDF11 release by ELISA. PCSK5 T288P was included as a catalytically dead control ( 28 ). B, GDF11 release by PCSK5 M452I plus wildtype PCSK5 (PCSK5 WT ) is additive. Cells were treated as in ( A ) and compared with 1.5 ng PCSK5 WT plus 1.5 ng PCSK5 M452I . C, Cotransfection with oncogenic HRAS G12V approximates the level of prenylated HRAS (HRAS prenyl ) in MCF10DCIS.com. 293T cells were lipofected with 2 ng of HRAS G12V and 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) and immunoblotted for HRAS with vinculin and p38 used as loading controls. MCF10A-5E cells are a negative control for HRAS overexpression. D, HRAS G12V cotransfection does not alter the relative GDF11 secretion efficiencies of wildtype PCSK5, PCSK5 M452I , and PCSK5 T288P . Cells were treated as in ( C ) and measured for GDF11 release by ELISA. For ( A ), ( B ), and ( D ), GDF11 ELISA results are normalized to the GDF11-only condition [gray dashed in ( A )] and shown as the mean ± SEM of N = 4 biological replicates. Differences among +GDF11 groups were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis.
    Anti Gdf11, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/GDF-11+Antibody/pmc12576568-85-1-2
    Average 93 stars, based on 1 article reviews
    anti gdf11 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    86
    Vigene Biosciences lentiviral particles downregulating gdf11
    METTL3 regulates <t>GDF11</t> through specific m 6 A modification sites. ( A – C ) HEK293T cells transduced with METTL3-overexpressing or control lentivirus, n = 3 independent experiments. ( A ) Relative expression of METTL3 mRNA, ( B ) GDF11 m 6 A modification levels and ( C ) GDF11 mRNA in HEK293T cells overexpressing METTL3. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference between two groups. ( D ) RIP assay showing the enrichment of GDF11 in METTL3 antibody pulldowns, n = 3 independent experiments. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference compared to the IgG control. ( E ) Prediction of m 6 A modification sites on GDF11 using the SRAMP database. ( F ) Four high-confidence sites were identified. ( G – J ) Dual-luciferase reporter assay showing the effect of METTL3 overexpression on luciferase activity at predicted m 6 A sites, n = 3 independent experiments. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference compared to the control. ( K ) GDF11 mRNA in HEK293T cells overexpressing METTL3 treated with Actinomycin D at 0, 4, 8, and 12 h, n = 3 independent experiments. Data are presented as mean ± SD. p <0.01 indicates a statistically significant difference compared to the control.
    Lentiviral Particles Downregulating Gdf11, supplied by Vigene Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/aav8/pmc12450055-32-13-22
    Average 86 stars, based on 1 article reviews
    lentiviral particles downregulating gdf11 - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Hirschmann gdf11 levels
    METTL3 regulates <t>GDF11</t> through specific m 6 A modification sites. ( A – C ) HEK293T cells transduced with METTL3-overexpressing or control lentivirus, n = 3 independent experiments. ( A ) Relative expression of METTL3 mRNA, ( B ) GDF11 m 6 A modification levels and ( C ) GDF11 mRNA in HEK293T cells overexpressing METTL3. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference between two groups. ( D ) RIP assay showing the enrichment of GDF11 in METTL3 antibody pulldowns, n = 3 independent experiments. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference compared to the IgG control. ( E ) Prediction of m 6 A modification sites on GDF11 using the SRAMP database. ( F ) Four high-confidence sites were identified. ( G – J ) Dual-luciferase reporter assay showing the effect of METTL3 overexpression on luciferase activity at predicted m 6 A sites, n = 3 independent experiments. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference compared to the control. ( K ) GDF11 mRNA in HEK293T cells overexpressing METTL3 treated with Actinomycin D at 0, 4, 8, and 12 h, n = 3 independent experiments. Data are presented as mean ± SD. p <0.01 indicates a statistically significant difference compared to the control.
    Gdf11 Levels, supplied by Hirschmann, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gdf11/gdf11+levels/pm40946799-259-42-20
    Average 86 stars, based on 1 article reviews
    gdf11 levels - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    Image Search Results


    293T cells co-expressing PCSK5 M452I secrete mature ectopic GDF11 with intermediate efficiency. A, Catalytically active PCSK5 promotes ectopic GDF11 secretion. Cells were lipofected with 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) plus 100 ng of GDF11, and conditioned medium was collected after 24 hours to measure GDF11 release by ELISA. PCSK5 T288P was included as a catalytically dead control ( 28 ). B, GDF11 release by PCSK5 M452I plus wildtype PCSK5 (PCSK5 WT ) is additive. Cells were treated as in ( A ) and compared with 1.5 ng PCSK5 WT plus 1.5 ng PCSK5 M452I . C, Cotransfection with oncogenic HRAS G12V approximates the level of prenylated HRAS (HRAS prenyl ) in MCF10DCIS.com. 293T cells were lipofected with 2 ng of HRAS G12V and 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) and immunoblotted for HRAS with vinculin and p38 used as loading controls. MCF10A-5E cells are a negative control for HRAS overexpression. D, HRAS G12V cotransfection does not alter the relative GDF11 secretion efficiencies of wildtype PCSK5, PCSK5 M452I , and PCSK5 T288P . Cells were treated as in ( C ) and measured for GDF11 release by ELISA. For ( A ), ( B ), and ( D ), GDF11 ELISA results are normalized to the GDF11-only condition [gray dashed in ( A )] and shown as the mean ± SEM of N = 4 biological replicates. Differences among +GDF11 groups were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis.

    Journal: Molecular cancer research : MCR

    Article Title: PCSK5 M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells

    doi: 10.1158/1541-7786.MCR-25-0211

    Figure Lengend Snippet: 293T cells co-expressing PCSK5 M452I secrete mature ectopic GDF11 with intermediate efficiency. A, Catalytically active PCSK5 promotes ectopic GDF11 secretion. Cells were lipofected with 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) plus 100 ng of GDF11, and conditioned medium was collected after 24 hours to measure GDF11 release by ELISA. PCSK5 T288P was included as a catalytically dead control ( 28 ). B, GDF11 release by PCSK5 M452I plus wildtype PCSK5 (PCSK5 WT ) is additive. Cells were treated as in ( A ) and compared with 1.5 ng PCSK5 WT plus 1.5 ng PCSK5 M452I . C, Cotransfection with oncogenic HRAS G12V approximates the level of prenylated HRAS (HRAS prenyl ) in MCF10DCIS.com. 293T cells were lipofected with 2 ng of HRAS G12V and 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) and immunoblotted for HRAS with vinculin and p38 used as loading controls. MCF10A-5E cells are a negative control for HRAS overexpression. D, HRAS G12V cotransfection does not alter the relative GDF11 secretion efficiencies of wildtype PCSK5, PCSK5 M452I , and PCSK5 T288P . Cells were treated as in ( C ) and measured for GDF11 release by ELISA. For ( A ), ( B ), and ( D ), GDF11 ELISA results are normalized to the GDF11-only condition [gray dashed in ( A )] and shown as the mean ± SEM of N = 4 biological replicates. Differences among +GDF11 groups were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis.

    Article Snippet: Concentrated samples were stored at −80°C, volumed up to 205 μl with Reagent Diluent (R&D Systems, DY008B) after thawing, and measured with the GDF11 ELISA (R&D Systems, DY1958) after adding two extended serial dilutions of recombinant GDF11 (15.5 pg/ml and 7.75 pg/ml).

    Techniques: Expressing, Over Expression, Control, Enzyme-linked Immunosorbent Assay, Cotransfection, Negative Control

    Inducible reconstitution of PCSK5 alleles in PCSK5 −/− MCF10DCIS.com cells. A, Approach to MCF10DCIS.com engineering. Cells were transduced with a destabilizing domain (DD)-containing Cas9-P2A-Venus ( 61 ) and a single-guide RNA targeting Exon 4 of PCSK5 (sgPCSK5). Transduced cells were treated with 200 nM Shield-1 ( 61 ) to stabilize Cas9-P2A-Venus and 2% matrigel to promote PCSK5 accessibility before sorting single Venus-positive cells into 10 ng/ml GDF11 (to aid recovery upon PCSK5 loss) and screening genomic DNA (gDNA) of expanded clones for knockout. One confirmed PCSK5 −/− clone was then transduced with sgPCSK5-resistant, tetracycline (tet)-regulated, V5-tagged alleles of PCSK5 and selected polyclonally for hygromycin resistance. B, Sequence-confirmed knockout alleles of MCF10DCIS.com clone 3D8. The PCSK5 coding sequence (CDS) is shown with annotations for the signal peptide (SP, purple), proprotein sequence (Pro, green), and peptidase domain (blue) including its catalytic triad (yellow stars). The protospacer adjacent motif (PAM) of sgPCSK5 is just upstream of the first triad amino acid, and deletions (white, Allele 1) or insertions (pink, Allele 2) induce frameshift mutations (gray) removing the first amino acid in the catalytic triad (black outlined stars) and producing premature stop codons (red). C, Quantification of reconstituted PCSK5 alleles by calibrating against recombinant V5-containing Multitag protein at the indicated copies per cell ( 63 , 72 ). Cells were treated with 1 μg/ml doxycycline for 24 hours, and total protein from counted cells was immunoblotted by two-color fluorescence detection for V5 (800 channel) with tubulin and p38 (700 channel) used as loading controls for cells. Copy number estimates are: PCSK5 WT , 136,000 ± 11,000 copies per cell; PCSK5 M452I , 164,000 ± 6,000 copies per cell; PCSK5 T288P , 176,000 ± 15,000 copies per cell ( N = 4 biological replicates).

    Journal: Molecular cancer research : MCR

    Article Title: PCSK5 M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells

    doi: 10.1158/1541-7786.MCR-25-0211

    Figure Lengend Snippet: Inducible reconstitution of PCSK5 alleles in PCSK5 −/− MCF10DCIS.com cells. A, Approach to MCF10DCIS.com engineering. Cells were transduced with a destabilizing domain (DD)-containing Cas9-P2A-Venus ( 61 ) and a single-guide RNA targeting Exon 4 of PCSK5 (sgPCSK5). Transduced cells were treated with 200 nM Shield-1 ( 61 ) to stabilize Cas9-P2A-Venus and 2% matrigel to promote PCSK5 accessibility before sorting single Venus-positive cells into 10 ng/ml GDF11 (to aid recovery upon PCSK5 loss) and screening genomic DNA (gDNA) of expanded clones for knockout. One confirmed PCSK5 −/− clone was then transduced with sgPCSK5-resistant, tetracycline (tet)-regulated, V5-tagged alleles of PCSK5 and selected polyclonally for hygromycin resistance. B, Sequence-confirmed knockout alleles of MCF10DCIS.com clone 3D8. The PCSK5 coding sequence (CDS) is shown with annotations for the signal peptide (SP, purple), proprotein sequence (Pro, green), and peptidase domain (blue) including its catalytic triad (yellow stars). The protospacer adjacent motif (PAM) of sgPCSK5 is just upstream of the first triad amino acid, and deletions (white, Allele 1) or insertions (pink, Allele 2) induce frameshift mutations (gray) removing the first amino acid in the catalytic triad (black outlined stars) and producing premature stop codons (red). C, Quantification of reconstituted PCSK5 alleles by calibrating against recombinant V5-containing Multitag protein at the indicated copies per cell ( 63 , 72 ). Cells were treated with 1 μg/ml doxycycline for 24 hours, and total protein from counted cells was immunoblotted by two-color fluorescence detection for V5 (800 channel) with tubulin and p38 (700 channel) used as loading controls for cells. Copy number estimates are: PCSK5 WT , 136,000 ± 11,000 copies per cell; PCSK5 M452I , 164,000 ± 6,000 copies per cell; PCSK5 T288P , 176,000 ± 15,000 copies per cell ( N = 4 biological replicates).

    Article Snippet: Concentrated samples were stored at −80°C, volumed up to 205 μl with Reagent Diluent (R&D Systems, DY008B) after thawing, and measured with the GDF11 ELISA (R&D Systems, DY1958) after adding two extended serial dilutions of recombinant GDF11 (15.5 pg/ml and 7.75 pg/ml).

    Techniques: Transduction, Clone Assay, Knock-Out, Sequencing, Recombinant, Fluorescence

    PCSK5 activity promotes rounded multi-cell organization in 3D matrigel cultures of MCF10DCIS.com. A, Spheroid growth rates for the indicated PCSK5 addback lines estimated by nonlinear least-squares regression of cross-sectional area ( 50 ) at 4, 8, and 12 days from N = 8 biological replicates (gray dashed). B and C , Reduced multi-cell circularity of MCF10DCIS.com upon loss of PCSK5. For ( B ), the scale bar is 100 μm. For ( C ), circularities were calculated from N = 1819 ( DCIS.com ) and 2028 (PCSK5 −/− ) segmented spheroids collected from 4 biological replicates at 16 days. Arcsine-transformed circularities were analyzed by two-sample homoscedastic t test. D and E, Multi-cell circularity of PCSK5 −/− cells is restored by wildtype PCSK5 or addition of 250 ng/ml recombinant GDF11, but not PCSK5 M452I or PCSK5 T288P . For ( D ), the scale bar is 100 μm. For ( E ), circularities were calculated from N = 5503 (wildtype PCSK5), 5016 (PCSK5 M452I ), 3495 (PCSK5 T288P ), and 3815 (PCSK5 T288P +GDF11) segmented spheroids collected from 8 biological replicates at 8 days, and arcsine-transformed circularities were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis. F and G , PCSK5 alleles do not alter the differentiation phenotypes of MCF10DCIS.com cells in 3D matrigel culture. Cultures in ( A ) plus PCSK5 T288P +GDF11 cultures were lysed and immunoblotted for CDH1, TP63, and VIM with vinculin, tubulin, ERK1/2, and p38 used as loading controls. For ( G ), data from N = 4 biological replicates were normalized to the mean of wildtype PCSK5 cultures, and the three unstimulated genotypes were Box-Cox-transformed and compared by multiway ANOVA with PCSK5 genotype as a fixed effect.

    Journal: Molecular cancer research : MCR

    Article Title: PCSK5 M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells

    doi: 10.1158/1541-7786.MCR-25-0211

    Figure Lengend Snippet: PCSK5 activity promotes rounded multi-cell organization in 3D matrigel cultures of MCF10DCIS.com. A, Spheroid growth rates for the indicated PCSK5 addback lines estimated by nonlinear least-squares regression of cross-sectional area ( 50 ) at 4, 8, and 12 days from N = 8 biological replicates (gray dashed). B and C , Reduced multi-cell circularity of MCF10DCIS.com upon loss of PCSK5. For ( B ), the scale bar is 100 μm. For ( C ), circularities were calculated from N = 1819 ( DCIS.com ) and 2028 (PCSK5 −/− ) segmented spheroids collected from 4 biological replicates at 16 days. Arcsine-transformed circularities were analyzed by two-sample homoscedastic t test. D and E, Multi-cell circularity of PCSK5 −/− cells is restored by wildtype PCSK5 or addition of 250 ng/ml recombinant GDF11, but not PCSK5 M452I or PCSK5 T288P . For ( D ), the scale bar is 100 μm. For ( E ), circularities were calculated from N = 5503 (wildtype PCSK5), 5016 (PCSK5 M452I ), 3495 (PCSK5 T288P ), and 3815 (PCSK5 T288P +GDF11) segmented spheroids collected from 8 biological replicates at 8 days, and arcsine-transformed circularities were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis. F and G , PCSK5 alleles do not alter the differentiation phenotypes of MCF10DCIS.com cells in 3D matrigel culture. Cultures in ( A ) plus PCSK5 T288P +GDF11 cultures were lysed and immunoblotted for CDH1, TP63, and VIM with vinculin, tubulin, ERK1/2, and p38 used as loading controls. For ( G ), data from N = 4 biological replicates were normalized to the mean of wildtype PCSK5 cultures, and the three unstimulated genotypes were Box-Cox-transformed and compared by multiway ANOVA with PCSK5 genotype as a fixed effect.

    Article Snippet: Concentrated samples were stored at −80°C, volumed up to 205 μl with Reagent Diluent (R&D Systems, DY008B) after thawing, and measured with the GDF11 ELISA (R&D Systems, DY1958) after adding two extended serial dilutions of recombinant GDF11 (15.5 pg/ml and 7.75 pg/ml).

    Techniques: Activity Assay, Transformation Assay, Recombinant

    293T cells co-expressing PCSK5 M452I secrete mature ectopic GDF11 with intermediate efficiency. A, Catalytically active PCSK5 promotes ectopic GDF11 secretion. Cells were lipofected with 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) plus 100 ng of GDF11, and conditioned medium was collected after 24 hours to measure GDF11 release by ELISA. PCSK5 T288P was included as a catalytically dead control ( 28 ). B, GDF11 release by PCSK5 M452I plus wildtype PCSK5 (PCSK5 WT ) is additive. Cells were treated as in ( A ) and compared with 1.5 ng PCSK5 WT plus 1.5 ng PCSK5 M452I . C, Cotransfection with oncogenic HRAS G12V approximates the level of prenylated HRAS (HRAS prenyl ) in MCF10DCIS.com. 293T cells were lipofected with 2 ng of HRAS G12V and 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) and immunoblotted for HRAS with vinculin and p38 used as loading controls. MCF10A-5E cells are a negative control for HRAS overexpression. D, HRAS G12V cotransfection does not alter the relative GDF11 secretion efficiencies of wildtype PCSK5, PCSK5 M452I , and PCSK5 T288P . Cells were treated as in ( C ) and measured for GDF11 release by ELISA. For ( A ), ( B ), and ( D ), GDF11 ELISA results are normalized to the GDF11-only condition [gray dashed in ( A )] and shown as the mean ± SEM of N = 4 biological replicates. Differences among +GDF11 groups were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis.

    Journal: Molecular cancer research : MCR

    Article Title: PCSK5 M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells

    doi: 10.1158/1541-7786.MCR-25-0211

    Figure Lengend Snippet: 293T cells co-expressing PCSK5 M452I secrete mature ectopic GDF11 with intermediate efficiency. A, Catalytically active PCSK5 promotes ectopic GDF11 secretion. Cells were lipofected with 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) plus 100 ng of GDF11, and conditioned medium was collected after 24 hours to measure GDF11 release by ELISA. PCSK5 T288P was included as a catalytically dead control ( 28 ). B, GDF11 release by PCSK5 M452I plus wildtype PCSK5 (PCSK5 WT ) is additive. Cells were treated as in ( A ) and compared with 1.5 ng PCSK5 WT plus 1.5 ng PCSK5 M452I . C, Cotransfection with oncogenic HRAS G12V approximates the level of prenylated HRAS (HRAS prenyl ) in MCF10DCIS.com. 293T cells were lipofected with 2 ng of HRAS G12V and 3 ng of the indicated PCSK5 allele (or EGFP overexpression control) and immunoblotted for HRAS with vinculin and p38 used as loading controls. MCF10A-5E cells are a negative control for HRAS overexpression. D, HRAS G12V cotransfection does not alter the relative GDF11 secretion efficiencies of wildtype PCSK5, PCSK5 M452I , and PCSK5 T288P . Cells were treated as in ( C ) and measured for GDF11 release by ELISA. For ( A ), ( B ), and ( D ), GDF11 ELISA results are normalized to the GDF11-only condition [gray dashed in ( A )] and shown as the mean ± SEM of N = 4 biological replicates. Differences among +GDF11 groups were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis.

    Article Snippet: GDF11 secretion assay—pLX302 GDF11-V5 puro (RRID:Addgene_83097), pLX304 (wildtype) PCSK5-V5 blast (RRID:Addgene_83100), and pLX304 PCSK5 (T288P)-V5 blast (RRID:Addgene_83101) were described previously ( 28 ). pBabe GFP (RRID:Addgene_10668), pBabe puro HA PIK3CA H1047R (RRID:Addgene_12524), pHAGE GFP (RRID:Addgene_106281), and pHAGE PIK3CA H1047R (RRID:Addgene_116500) were commercially obtained. pDONR223 PCSK5 (M452I) (RRID:Addgene_232445) was prepared by QuikChange II XL site-directed mutagenesis (Agilent, 200521) of pDONR223 (wildtype) PCSK5 from the human ORFeome v5.1 and recombined into pLX304 (RRID:Addgene_25890) with LR clonase II (Invitrogen, 11791020) to yield pLX304 PCSK5 (M452I)-V5 blast (RRID:Addgene_232446). pDONR223 BMP2 and pDONR223 BMP4 from the human ORFeome v5.1 were similarly recombined into pLX302 (RRID:Addgene_25896) with LR clonase II (Invitrogen, 11791020) to yield pLX302 BMP2-V5 puro (RRID:Addgene_246525) and pLX302 BMP4-V5 puro (RRID:Addgene_246526). pcDNA3 was used as a carrier plasmid for lipofections, and pLX302 EGFP-V5 puro (RRID:Addgene_141348) or pLX304 EGFP-V5 blast (RRID:Addgene_232447) was used when diluting GDF11 or PCSK5 plasmid dosage and for negative controls. pcDNA3.1 HRAS (G12V) was kindly provided by David Kashatus.

    Techniques: Expressing, Over Expression, Control, Enzyme-linked Immunosorbent Assay, Cotransfection, Negative Control

    Inducible reconstitution of PCSK5 alleles in PCSK5 −/− MCF10DCIS.com cells. A, Approach to MCF10DCIS.com engineering. Cells were transduced with a destabilizing domain (DD)-containing Cas9-P2A-Venus ( 61 ) and a single-guide RNA targeting Exon 4 of PCSK5 (sgPCSK5). Transduced cells were treated with 200 nM Shield-1 ( 61 ) to stabilize Cas9-P2A-Venus and 2% matrigel to promote PCSK5 accessibility before sorting single Venus-positive cells into 10 ng/ml GDF11 (to aid recovery upon PCSK5 loss) and screening genomic DNA (gDNA) of expanded clones for knockout. One confirmed PCSK5 −/− clone was then transduced with sgPCSK5-resistant, tetracycline (tet)-regulated, V5-tagged alleles of PCSK5 and selected polyclonally for hygromycin resistance. B, Sequence-confirmed knockout alleles of MCF10DCIS.com clone 3D8. The PCSK5 coding sequence (CDS) is shown with annotations for the signal peptide (SP, purple), proprotein sequence (Pro, green), and peptidase domain (blue) including its catalytic triad (yellow stars). The protospacer adjacent motif (PAM) of sgPCSK5 is just upstream of the first triad amino acid, and deletions (white, Allele 1) or insertions (pink, Allele 2) induce frameshift mutations (gray) removing the first amino acid in the catalytic triad (black outlined stars) and producing premature stop codons (red). C, Quantification of reconstituted PCSK5 alleles by calibrating against recombinant V5-containing Multitag protein at the indicated copies per cell ( 63 , 72 ). Cells were treated with 1 μg/ml doxycycline for 24 hours, and total protein from counted cells was immunoblotted by two-color fluorescence detection for V5 (800 channel) with tubulin and p38 (700 channel) used as loading controls for cells. Copy number estimates are: PCSK5 WT , 136,000 ± 11,000 copies per cell; PCSK5 M452I , 164,000 ± 6,000 copies per cell; PCSK5 T288P , 176,000 ± 15,000 copies per cell ( N = 4 biological replicates).

    Journal: Molecular cancer research : MCR

    Article Title: PCSK5 M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells

    doi: 10.1158/1541-7786.MCR-25-0211

    Figure Lengend Snippet: Inducible reconstitution of PCSK5 alleles in PCSK5 −/− MCF10DCIS.com cells. A, Approach to MCF10DCIS.com engineering. Cells were transduced with a destabilizing domain (DD)-containing Cas9-P2A-Venus ( 61 ) and a single-guide RNA targeting Exon 4 of PCSK5 (sgPCSK5). Transduced cells were treated with 200 nM Shield-1 ( 61 ) to stabilize Cas9-P2A-Venus and 2% matrigel to promote PCSK5 accessibility before sorting single Venus-positive cells into 10 ng/ml GDF11 (to aid recovery upon PCSK5 loss) and screening genomic DNA (gDNA) of expanded clones for knockout. One confirmed PCSK5 −/− clone was then transduced with sgPCSK5-resistant, tetracycline (tet)-regulated, V5-tagged alleles of PCSK5 and selected polyclonally for hygromycin resistance. B, Sequence-confirmed knockout alleles of MCF10DCIS.com clone 3D8. The PCSK5 coding sequence (CDS) is shown with annotations for the signal peptide (SP, purple), proprotein sequence (Pro, green), and peptidase domain (blue) including its catalytic triad (yellow stars). The protospacer adjacent motif (PAM) of sgPCSK5 is just upstream of the first triad amino acid, and deletions (white, Allele 1) or insertions (pink, Allele 2) induce frameshift mutations (gray) removing the first amino acid in the catalytic triad (black outlined stars) and producing premature stop codons (red). C, Quantification of reconstituted PCSK5 alleles by calibrating against recombinant V5-containing Multitag protein at the indicated copies per cell ( 63 , 72 ). Cells were treated with 1 μg/ml doxycycline for 24 hours, and total protein from counted cells was immunoblotted by two-color fluorescence detection for V5 (800 channel) with tubulin and p38 (700 channel) used as loading controls for cells. Copy number estimates are: PCSK5 WT , 136,000 ± 11,000 copies per cell; PCSK5 M452I , 164,000 ± 6,000 copies per cell; PCSK5 T288P , 176,000 ± 15,000 copies per cell ( N = 4 biological replicates).

    Article Snippet: GDF11 secretion assay—pLX302 GDF11-V5 puro (RRID:Addgene_83097), pLX304 (wildtype) PCSK5-V5 blast (RRID:Addgene_83100), and pLX304 PCSK5 (T288P)-V5 blast (RRID:Addgene_83101) were described previously ( 28 ). pBabe GFP (RRID:Addgene_10668), pBabe puro HA PIK3CA H1047R (RRID:Addgene_12524), pHAGE GFP (RRID:Addgene_106281), and pHAGE PIK3CA H1047R (RRID:Addgene_116500) were commercially obtained. pDONR223 PCSK5 (M452I) (RRID:Addgene_232445) was prepared by QuikChange II XL site-directed mutagenesis (Agilent, 200521) of pDONR223 (wildtype) PCSK5 from the human ORFeome v5.1 and recombined into pLX304 (RRID:Addgene_25890) with LR clonase II (Invitrogen, 11791020) to yield pLX304 PCSK5 (M452I)-V5 blast (RRID:Addgene_232446). pDONR223 BMP2 and pDONR223 BMP4 from the human ORFeome v5.1 were similarly recombined into pLX302 (RRID:Addgene_25896) with LR clonase II (Invitrogen, 11791020) to yield pLX302 BMP2-V5 puro (RRID:Addgene_246525) and pLX302 BMP4-V5 puro (RRID:Addgene_246526). pcDNA3 was used as a carrier plasmid for lipofections, and pLX302 EGFP-V5 puro (RRID:Addgene_141348) or pLX304 EGFP-V5 blast (RRID:Addgene_232447) was used when diluting GDF11 or PCSK5 plasmid dosage and for negative controls. pcDNA3.1 HRAS (G12V) was kindly provided by David Kashatus.

    Techniques: Transduction, Clone Assay, Knock-Out, Sequencing, Recombinant, Fluorescence

    PCSK5 activity promotes rounded multi-cell organization in 3D matrigel cultures of MCF10DCIS.com. A, Spheroid growth rates for the indicated PCSK5 addback lines estimated by nonlinear least-squares regression of cross-sectional area ( 50 ) at 4, 8, and 12 days from N = 8 biological replicates (gray dashed). B and C , Reduced multi-cell circularity of MCF10DCIS.com upon loss of PCSK5. For ( B ), the scale bar is 100 μm. For ( C ), circularities were calculated from N = 1819 ( DCIS.com ) and 2028 (PCSK5 −/− ) segmented spheroids collected from 4 biological replicates at 16 days. Arcsine-transformed circularities were analyzed by two-sample homoscedastic t test. D and E, Multi-cell circularity of PCSK5 −/− cells is restored by wildtype PCSK5 or addition of 250 ng/ml recombinant GDF11, but not PCSK5 M452I or PCSK5 T288P . For ( D ), the scale bar is 100 μm. For ( E ), circularities were calculated from N = 5503 (wildtype PCSK5), 5016 (PCSK5 M452I ), 3495 (PCSK5 T288P ), and 3815 (PCSK5 T288P +GDF11) segmented spheroids collected from 8 biological replicates at 8 days, and arcsine-transformed circularities were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis. F and G , PCSK5 alleles do not alter the differentiation phenotypes of MCF10DCIS.com cells in 3D matrigel culture. Cultures in ( A ) plus PCSK5 T288P +GDF11 cultures were lysed and immunoblotted for CDH1, TP63, and VIM with vinculin, tubulin, ERK1/2, and p38 used as loading controls. For ( G ), data from N = 4 biological replicates were normalized to the mean of wildtype PCSK5 cultures, and the three unstimulated genotypes were Box-Cox-transformed and compared by multiway ANOVA with PCSK5 genotype as a fixed effect.

    Journal: Molecular cancer research : MCR

    Article Title: PCSK5 M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells

    doi: 10.1158/1541-7786.MCR-25-0211

    Figure Lengend Snippet: PCSK5 activity promotes rounded multi-cell organization in 3D matrigel cultures of MCF10DCIS.com. A, Spheroid growth rates for the indicated PCSK5 addback lines estimated by nonlinear least-squares regression of cross-sectional area ( 50 ) at 4, 8, and 12 days from N = 8 biological replicates (gray dashed). B and C , Reduced multi-cell circularity of MCF10DCIS.com upon loss of PCSK5. For ( B ), the scale bar is 100 μm. For ( C ), circularities were calculated from N = 1819 ( DCIS.com ) and 2028 (PCSK5 −/− ) segmented spheroids collected from 4 biological replicates at 16 days. Arcsine-transformed circularities were analyzed by two-sample homoscedastic t test. D and E, Multi-cell circularity of PCSK5 −/− cells is restored by wildtype PCSK5 or addition of 250 ng/ml recombinant GDF11, but not PCSK5 M452I or PCSK5 T288P . For ( D ), the scale bar is 100 μm. For ( E ), circularities were calculated from N = 5503 (wildtype PCSK5), 5016 (PCSK5 M452I ), 3495 (PCSK5 T288P ), and 3815 (PCSK5 T288P +GDF11) segmented spheroids collected from 8 biological replicates at 8 days, and arcsine-transformed circularities were analyzed by multiway ANOVA with PCSK5 genotype as a fixed effect. Significant factors were followed up pairwise by Tukey-Kramer post hoc analysis. F and G , PCSK5 alleles do not alter the differentiation phenotypes of MCF10DCIS.com cells in 3D matrigel culture. Cultures in ( A ) plus PCSK5 T288P +GDF11 cultures were lysed and immunoblotted for CDH1, TP63, and VIM with vinculin, tubulin, ERK1/2, and p38 used as loading controls. For ( G ), data from N = 4 biological replicates were normalized to the mean of wildtype PCSK5 cultures, and the three unstimulated genotypes were Box-Cox-transformed and compared by multiway ANOVA with PCSK5 genotype as a fixed effect.

    Article Snippet: GDF11 secretion assay—pLX302 GDF11-V5 puro (RRID:Addgene_83097), pLX304 (wildtype) PCSK5-V5 blast (RRID:Addgene_83100), and pLX304 PCSK5 (T288P)-V5 blast (RRID:Addgene_83101) were described previously ( 28 ). pBabe GFP (RRID:Addgene_10668), pBabe puro HA PIK3CA H1047R (RRID:Addgene_12524), pHAGE GFP (RRID:Addgene_106281), and pHAGE PIK3CA H1047R (RRID:Addgene_116500) were commercially obtained. pDONR223 PCSK5 (M452I) (RRID:Addgene_232445) was prepared by QuikChange II XL site-directed mutagenesis (Agilent, 200521) of pDONR223 (wildtype) PCSK5 from the human ORFeome v5.1 and recombined into pLX304 (RRID:Addgene_25890) with LR clonase II (Invitrogen, 11791020) to yield pLX304 PCSK5 (M452I)-V5 blast (RRID:Addgene_232446). pDONR223 BMP2 and pDONR223 BMP4 from the human ORFeome v5.1 were similarly recombined into pLX302 (RRID:Addgene_25896) with LR clonase II (Invitrogen, 11791020) to yield pLX302 BMP2-V5 puro (RRID:Addgene_246525) and pLX302 BMP4-V5 puro (RRID:Addgene_246526). pcDNA3 was used as a carrier plasmid for lipofections, and pLX302 EGFP-V5 puro (RRID:Addgene_141348) or pLX304 EGFP-V5 blast (RRID:Addgene_232447) was used when diluting GDF11 or PCSK5 plasmid dosage and for negative controls. pcDNA3.1 HRAS (G12V) was kindly provided by David Kashatus.

    Techniques: Activity Assay, Transformation Assay, Recombinant

    METTL3 regulates GDF11 through specific m 6 A modification sites. ( A – C ) HEK293T cells transduced with METTL3-overexpressing or control lentivirus, n = 3 independent experiments. ( A ) Relative expression of METTL3 mRNA, ( B ) GDF11 m 6 A modification levels and ( C ) GDF11 mRNA in HEK293T cells overexpressing METTL3. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference between two groups. ( D ) RIP assay showing the enrichment of GDF11 in METTL3 antibody pulldowns, n = 3 independent experiments. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference compared to the IgG control. ( E ) Prediction of m 6 A modification sites on GDF11 using the SRAMP database. ( F ) Four high-confidence sites were identified. ( G – J ) Dual-luciferase reporter assay showing the effect of METTL3 overexpression on luciferase activity at predicted m 6 A sites, n = 3 independent experiments. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference compared to the control. ( K ) GDF11 mRNA in HEK293T cells overexpressing METTL3 treated with Actinomycin D at 0, 4, 8, and 12 h, n = 3 independent experiments. Data are presented as mean ± SD. p <0.01 indicates a statistically significant difference compared to the control.

    Journal: Diabetes, Metabolic Syndrome and Obesity

    Article Title: METTL3-Mediated m 6 A Regulation of GDF11 Promotes Socket Healing in Diabetic Rats

    doi: 10.2147/DMSO.S536806

    Figure Lengend Snippet: METTL3 regulates GDF11 through specific m 6 A modification sites. ( A – C ) HEK293T cells transduced with METTL3-overexpressing or control lentivirus, n = 3 independent experiments. ( A ) Relative expression of METTL3 mRNA, ( B ) GDF11 m 6 A modification levels and ( C ) GDF11 mRNA in HEK293T cells overexpressing METTL3. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference between two groups. ( D ) RIP assay showing the enrichment of GDF11 in METTL3 antibody pulldowns, n = 3 independent experiments. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference compared to the IgG control. ( E ) Prediction of m 6 A modification sites on GDF11 using the SRAMP database. ( F ) Four high-confidence sites were identified. ( G – J ) Dual-luciferase reporter assay showing the effect of METTL3 overexpression on luciferase activity at predicted m 6 A sites, n = 3 independent experiments. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference compared to the control. ( K ) GDF11 mRNA in HEK293T cells overexpressing METTL3 treated with Actinomycin D at 0, 4, 8, and 12 h, n = 3 independent experiments. Data are presented as mean ± SD. p <0.01 indicates a statistically significant difference compared to the control.

    Article Snippet: After dental extraction, GK rats were administered lentiviral particles overexpressing METTL3 (LV-METTL3) or lentiviral particles downregulating GDF11 (LV-shGDF11) at the extraction sites (Vigene Biosciences).

    Techniques: Modification, Transduction, Control, Expressing, Luciferase, Reporter Assay, Over Expression, Activity Assay

    Knockdown of GDF11 partially reverses the tooth extraction socket healing effects of METTL3 overexpression. ( A ) Relative expression of GDF11 in the different groups, n = 6 sockets per group. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference between the LV-shGDF11 group and the LV-shNC group. ( B ) Representative images showing tooth extraction socket healing at the tooth extraction sites in Wistar control, GK, GK+LV-NC, GK+LV-METTL3, GK+LV-METTL3+LV-shNC, and GK+LV-METTL3+LV-shGDF11 groups, n = 6 sockets per group. ( C – F ) BV/TV, Tb.N, Tb.Th, and Tb.Sp in the extraction socket 21 days after tooth extraction, n = 6 sockets per group. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference between groups.

    Journal: Diabetes, Metabolic Syndrome and Obesity

    Article Title: METTL3-Mediated m 6 A Regulation of GDF11 Promotes Socket Healing in Diabetic Rats

    doi: 10.2147/DMSO.S536806

    Figure Lengend Snippet: Knockdown of GDF11 partially reverses the tooth extraction socket healing effects of METTL3 overexpression. ( A ) Relative expression of GDF11 in the different groups, n = 6 sockets per group. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference between the LV-shGDF11 group and the LV-shNC group. ( B ) Representative images showing tooth extraction socket healing at the tooth extraction sites in Wistar control, GK, GK+LV-NC, GK+LV-METTL3, GK+LV-METTL3+LV-shNC, and GK+LV-METTL3+LV-shGDF11 groups, n = 6 sockets per group. ( C – F ) BV/TV, Tb.N, Tb.Th, and Tb.Sp in the extraction socket 21 days after tooth extraction, n = 6 sockets per group. Data are presented as mean ± SD. p <0.001 indicates a statistically significant difference between groups.

    Article Snippet: After dental extraction, GK rats were administered lentiviral particles overexpressing METTL3 (LV-METTL3) or lentiviral particles downregulating GDF11 (LV-shGDF11) at the extraction sites (Vigene Biosciences).

    Techniques: Knockdown, Extraction, Over Expression, Expressing, Control